Category: Hiring/layoffs
-
Sanofi to Cut Genzyme Massachusetts Research Staff
The French pharmaceutical maker Sanofi says it will reduce its research workforce employed in and around Boston, as a result of its acquisition of Genzyme Corporation a year ago. Sanofi confirmed the cuts today in a statement to the industry Web site Fierce Biotech. Genzyme, headquartered in Cambridge, Massachusetts, was acquired by Sanofi last year…
-
Novo Nordisk to Add New Diabetes R&D Center in Seattle
The Danish drug maker Novo Nordisk says it will add a new research facility to study type 1 diabetes in Seattle, Washington. The lab is expected to open this summer and employ 20 researchers on the site of its current inflammation research center. Novo Nordisk says the new lab will conduct translational studies that combine…
-
Report: Asia Closing Gap in U.S. R&D Leadership
National Science Foundation’s new report on global research and development (R&D) trends, Science and Engineering Indicators 2012, shows in the last decade, U.S. leadership in research and development has come under severe challenge from China and other countries in Asia. The report from NSF’s policy-making body, the National Science Board, shows between 1999 and 2009,…
-
BASF to Move Plant Biotech Work to U.S. from Germany
The German chemical company BASF says it will move much of its plant science R&D work to the U.S. to take advantage of a more favorable regulatory climate than in Europe. The company expects to relocate its facilities in Limburgerhof, Germany and elsewhere in Europe to a new site in Research Triangle Park near Raleigh,…
-
Novartis to Restructure, Cut 1,960 U.S. Jobs
The Swiss company Novartis Pharmaceuticals said on Friday it plans to reorganize its General Medicines division in the U.S. resulting in a loss of 1,960 jobs. The company said it expects the job cuts to take place in the second quarter of 2012. Novartis plans to reduce its General Medicines field workforce by 1,630 jobs…
-
Geron Halts Embryonic Stem Cell Research, Clinical Trial
Geron Corporation, a biotechnology company in Menlo Park, California, says it has discontinued its development of therapies based on human embryonic stem cells to focus on cancer drugs. The immediate results of its decision are to end a clinical trial of its stem cell drug on patients with spinal cord injuries — the first clinical…
-
Novartis to Cut Jobs in U.S., Switzerland; Add Jobs in Asia
In its third-quarter financial report released today, the Swiss pharmaceutical company Novartis AG said it would cut some 2,000 jobs in Switzerland and the U.S., but add 700 jobs in China and India. The cuts were announced at the same time the company said it recorded gains in third quarter sales of 12 percent and…
-
New On Technorati: Friendly to What Business?
High paying jobs are being created in large numbers right here in the U.S., and in places where the so-called experts say they’re not supposed to happen. If states want the big bucks from big brains and the benefits they bring, then they need to make the work being done and people doing the work…
-
Semiconductor Companies to Invest $4.4B in New York R&D
Five semiconductor developers said today they will make a joint investment of $4.4 billion over the next five years to develop new computer chip technologies in New York State. The companies include Intel Corporation, IBM, GlobalFoundries, Samsung, and Taiwan Semiconductor Manufacturing Company (TSMC). The investments will be made in current and upgraded facilities in Albany,…
-
Sandia Lab Contributes Nearly $1B to California Economy
An analysis of economic output generated by Sandia National Laboratories shows the lab contributes nearly $1 billion to the California economy, particularly in and around its Livermore campus in the Bay Area. The report was prepared by the Center for Economic Development (CED) at California State University in Chico. The CED report defines economic output…